Home » Newsletters » BioWorld

BioWorld

April 4, 2006

View Archived Issues

Veronate Data Crush Inhibitex; Drug's Future Cast Into Doubt

Shares in Inhibitex Inc. plunged by two-thirds Monday after the company released poor Phase III data on Veronate. (BioWorld Today) Read More

Sirna, GSK Enter Respiratory Deal Worth Up To $700M-Plus

Cancer Drug Developers Running Out Of Excuses

FDA Holds Up Cortex's CX717; Incyte Scratching DFC For HIV

EPIX Buying Predix For $90M, With $35M Milestone Potential

Merrimack's Series E: $65M For Autoimmune, Oncology

Other News To Note

Appointments And Advancements

Clinic Roundup